centanafadine capsule for Attention Deficit Hyperactivity Disorder (ADHD)
Study Summary
This trial will test how well centanafadine QD XR (a medication) works compared to placebo in treating children 4-12 years old with ADHD.
- Attention Deficit Hyperactivity Disorder (ADHD)
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
Does this research project have an age limit?
"The age range that is eligible for this clinical trial according to the current criteria is 4 to 12 years old."
Are people with the qualifying condition able to enroll in this research project at this time?
"That is correct. The website provides updated information that recruitment is ongoing for the 450 patients at a single site."
How many people are being included in this clinical trial?
"That is correct, the clinical trial mentioned is currently looking for patients. As seen on clinicaltrials.gov, the posting went up on 7/11/2022 and was updated as recently as 8/31/2022. They are aiming to have 450 people sign up in total from 1 location."
Who meets the inclusion criteria for this particular experiment?
"This study is looking for 450 young patients that have hyperkinesis. In order to be eligible, potential participants must meet the following requirements: They must be between 4 and 12 years old (inclusive), have a primary diagnosis of ADHD based on DSM-5 criteria as confirmed with the MINI-KID, have a minimum symptoms total raw score of ≥ 28 on the ADHD-RS-5 at baseline, score 4 or higher on the CGI-S-ADHD at baseline, and if they are aged 4 or 5 years only: has failed adequate psychotherapy or in the investigator's opinion, is severe enough to"
Are there any harmful side effects associated with taking centanafadine capsules?
"Centanafadine capsule safety is rated a 3 because it has undergone Phase 3 clinical trials. This indicates that, while more research needs to be done, the drug's efficacy has been supported and multiple rounds of data support its safety."